Harvest SSE STAR Biology and Medicine ETF

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

RemeGen Approves 2.5B RMB Cash Management Plan, Invests 453M with HTSC in Fixed Income Products

Baili Tianheng's Innovative Drug SI-B036 Approved for Clinical Trials in Late-Stage Solid Tumors by NMPA

BeiGene's Brukinsa Approved by FDA

Rongchang Biotech Purchases Multiple Wealth Management Products from SPDB Yantai Branch

Belayidiantianheng Receives Approval for Clinical Trials of Iza-bren Combination Therapy

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

CMBC International and DBS Maintain Buy Rating for BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

Belayzhizun (BeiJing) Q1 Earnings Exceed Expectations

BeiGene Releases Q1 2026 Financial Report and Revises Financial Guidance

Beyterzelk and Amgen Authorized Products Drive First Quarter 2026 Revenue Growth for BeiGene

BeiGene Adjusts 2026 Full-Year Operating Performance Forecast

BeOne Medicines released FY2026 Q1 earnings on May 6 Pre-Market (BJT), actual revenue CNY 10.46 B (forecast CNY 9.93 B), actual EPS CNY 1.0368

BeiGene Secures Global Rights to Huaheng's Tri-Antibody for $20 Million

BrightGene released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 324.93 M, actual EPS CNY 0.02

BeOne Medicines to Release FY2026 Q1 Earnings on May 6 Pre-Market (BJT), Forecast Revenue CNY 9.835 B

BofA Securities Notes BeiGene's Pharmaceutical Sales Growth Maintains Buy Rating

Zelgen released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 905.39 M, actual EPS CNY 2.39

600547

GDXW

588700

<p>Last week (from March 30 to April 3), the Shanghai Composite Index slightly fell by 0.86%, while the growth style index was significantly adjusted downwards. The pharmaceutical commerce and precious metals sectors performed strongly, with the innovative drug ETF leading the gains, and the ICBC Innovative Drug ETF rising by 6.9%. Despite a net outflow of 4.042 billion yuan in the overall ETF market and an outflow of 12.117 billion yuan in equity ETFs, bond, commodity, and currency ETFs all achieved net inflows. The Hong Kong innovative drug market has stabilized, with low valuations and ample room for allocation, and the industry's fundamentals have improved, indicating that the subsequent market trend is expected to fluctuate upwards</p>

腾讯新闻 - 财经

SD-GOLD

Roundhill Gold Miners Weeklypay ETF

ZHONGJIN GOLD

GF CSI HK Innovative Drugs Industry ETF(QDII)

EFUND GOLD MI ETF

Pro Ultr GLD

Harvest CSI Hong Kong Connect Innovative Drugs ETF

SPDR GOLD TRT

Microsectors Gold Miners 3x Leveraged ETN

iShares MSCI Global Gold Miners

Yinhua CNI HK Connect Innovative Drugs ETF

Direxion Daily Jr Gold Miners Bull 2X

GLOBAL X Gold Explorers

ChinaAMC Gold ETF

Direxion Daily Gold Miners Bull 2X

VanEck Gold Miners ETF

SPDR Gold Minishares

Sprott GLD Miners Etf

EFUND GOLD MI-U

Us Gbl GLD & Met

ICBCCS CSI Brand Name Drug Industry ETF

EFUND GOLD MI-R

YieldMax Gold Miners Opt Inc Strgy ETF

Sprott JR Gold Miners ETF

Zijin Mining

Abrdn Gold ETF Trust

ICBCCS CNI HK Connect Innovative Drugs ETF

ETF Weekly Review: Innovative Drugs Dominate the Rankings, Gold Strongly Attracts Capital

588860

516500

<p>As of January 29, nearly 250 companies on the STAR Market have disclosed their performance expectations for 2025, with 125 companies expecting to be profitable, accounting for about 50%. 67 companies expect positive net profit growth, and 29 companies expect to double their performance. Emerging industries such as semiconductors, biomedicine, and artificial intelligence have performed well due to market demand recovery and improvements in their main businesses</p>

Wallstreetcn

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai SSE STAR Artificial Intelligence ETF

STAR 50

Guotai SSE STAR Chip ETF

Redwall

E Fund SSE STAR Artificial Intelligence ETF

Hwabao WP SSE STAR Artificial Intelligence ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua SSE STAR Artificial Intelligence ETF

E Fund CSI Biotechnology Theme ETF

New technologies and new products stimulate new momentum, STAR Market companies "reveal" the secrets of performance growth

Harvest SSE STAR Biology and Medicine ETF(588700.SH)

ETF Weekly Review: Innovative Drugs Dominate the Rankings, Gold Strongly Attracts Capital

New technologies and new products stimulate new momentum, STAR Market companies "reveal" the secrets of performance growth